M2Bio Sciences Enters Into Letter Of Intent To Acquire Crypto Exchange JDAX
M2Bio Sciences Enters Into Letter Of Intent To Acquire Crypto Exchange JDAX. M2Bio Sciences is thrilled to announce the signing of a letter of intent to acquire JDAX, a major cryptocurrency platform facilitating seamless exchange, trading, and secure storage of digital currencies.
Functioning as a cutting-edge digital marketplace, JDAX empowers users to buy, sell, and hold a wide range of cryptocurrencies. Moreover, it facilitates essential activities such as managing digital wallets, executing trades, and accessing comprehensive market data.
JDAX, the Johannesburg Digital Assets Exchange, represents a notable South African Fintech company immersed in the realms of Blockchain, Web3, and Decentralized Finance (DeFi) technologies. By positioning itself at the forefront of these advancements, M2Bio aims to accelerate the traditionally challenging and time-consuming process of natural product drug discovery. Through collaborations with prestigious universities and the support of multiple funded research chairs, the M2Bio Research Team is engaged in the extraction of bioactive compounds from an extensive collection of African plants renowned for their potential efficacy. Leveraging novel extraction methods and AI models, M2Bio exponentially enhances the pace of discovery and characterization of potentially bioactive compounds.
At this opportune moment, M2Bio aligns itself with the rapid progress of AI and its broad applications. The acquisition of JDAX is an integral part of M2Bio’s overarching strategy to establish a humanity-centric enterprise. By leveraging JDAX’s blockchain technology, M2Bio envisions a future where research projects can be tokenized. This allows for decentralized ownership and the potential issuance of Non-Fungible Tokens (NFTs) representing fractional ownership rights over the discovered molecules. Ze-ev Krein, an interdisciplinary scientist and the founder of JDAX, will guide M2Bio’s drug discovery program and will spearhead the development of smart contracts that enable global communities to actively participate in and potentially hold ownership stakes in the transformative discoveries arising from M2Bio’s research efforts.
Ze-ev Krein, drawing on his background in medicinal chemistry, computer science, economics, and law, expressed his vision for JDAX, stating: “Our ultimate goal has always been to create a platform that funds projects capable of bringing about impactful changes for humanity. M2Bio’s acquisition will catalyze this ambition. As a scientist, I firmly believe that the most significant obstacle to scientific discovery lies not in the capabilities of researchers, but in the rigidity of financial systems. AI, Web3, and decentralized finance possess the power to dismantle these primitive boundaries. In this unique endeavor, we aim to lead the way in revolutionizing phytomedicine discovery.”
Jeff Robinson, M2Bio Sciences, Inc CEO added: “At M2Bio we are always working on finding unique ways to deploy cutting-edge technologies in order to advance medicine. Altcoins and NFTs are here to stay and are slowly but surely becoming part of our everyday lives. Creating an NFT using the crystal structure of a molecule can serve as a fascinating way to merge science and art, showcasing the beauty and complexity of molecular structures in a digital medium. These representations can include the three-dimensional arrangement of atoms, molecular bonds, and the overall crystal lattice structure. It will appeal to a wide range of audiences, including scientists, art enthusiasts, collectors, and individuals with an interest in both fields. In addition, it plays well into the human needs for ownership and authenticity. The NFT serves as a unique digital asset that can include relevant information such as the name of the compound, its therapeutic potential, key research details, and associated images or videos. And the blockchain’s immutable nature ensures that the ownership history and details associated with the NFT are securely recorded and verifiable. Without a doubt, this space will become a trillion-dollar opportunity. It feels great to be offering a real-world use case scenario to the world and not just another fatigued ape.”
